Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.2415

Phase II Study on Voriconazole for Treatment of Chinese Patients with Malignant Hematological Disorders and Invasive Aspergillosis  

Zhang, Xue-Zhong (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
Huang, Xin-En (Department of Chemotherapy, JiangSu Cancer Hospital and Research Institute)
Xu, Yan-Li (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
Zhang, Xiu-Qun (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
Su, Ai-ling (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
Shen, Zheng-Shan (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 2415-2418 More about this Journal
Abstract
Objective: To investigate the efficacy and safety of voriconazole in treating Chinese patients with hematological malignancies and invasive aspergillosis. Methods: From March 2007 to April 2012, patients with diagnoses confirmed by CT, GM test and/or PCR assays, were recruited into this study. Aspergillosis of all patients were treated with voriconazole 6 mg/kg intravenous infusion (iv) every 12 h for 1 day, followed by 4 mg/kg IV every 12 h for 10-15 days; Then, switch to oral administration that was 200mg every 12h for 4-12 weeks. Efficacy and safety were evaluated according to Practice Guideline of Infectious Diseases Society of America. Results: The overall response rate of 38 patients after voriconazole treatment was 81.6%. The median time to pyretolysis was 4.5 days. Treatment related side effects were mild and found in only 15.8% of cases. No treatment related deaths occurred. Conclusions: Voriconazole can considered to be a safe and effective front-line therapy to treat patients with hematological malignancies and invasive aspergillosis. Alternatively it could be used as a remedial treatment when other antifungal therapies are ineffective.
Keywords
Hematological disorders; aspergillus; voriconazole;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Baddley JW, Andes DR, Marr KA, et al (2012). Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol. 2012 Jun 11.
2 Egerer G, Reichert D, Pletz MW, et al (2012). Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry. Eur J Med Res, 17, 7.   DOI
3 Herbrecht R, Denning DW, Patterson TF, et al (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, 408-15.   DOI   ScienceOn
4 Hilde VC, Sophie M, Marie-Paule D, et al (2008). Voriconazole treatment of invasive aspergillosis. Clin Drug Invest, 28, 509-21.   DOI
5 Hoenigl M, Strenger V, Buzina W, et al (2012). European Organization for the Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. published online on May 7, 2012 and accessed on Jun 2nd, 2012.
6 Horbrecht R, Letscher-Bru V, Oprea C, et al (2002). Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol, 20, 1898-906.   DOI
7 Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
8 Huang XE, Li CG, Li Y, et al (2011). European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. Asian Pac J Cancer Prev, 12, 2797-800.
9 Georgiadou SP, Kontoyiannis DP, et al (2012). Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis? J Infect. 2012 May 9.
10 Godet C, Elsendoorn A, Roblot F, et al (2012). Benefit of CT scanning for assessing pulmonary disease in the immunodepressed patient. Diagn Interv Imaging, 93, 425-30.   DOI
11 Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, in press.
12 Hadrich I, Makni F, Neji S, et al (2012). Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol. 2012 May 15.
13 Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
14 Kriengkauykiat J, Ito JI, Dadwal SS (2011). Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol, 3, 175-91.
15 Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
16 Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
17 Mengoli C, Cruciani M, Barnes RA, et al (2009). Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis, 9, 89-96.   DOI
18 Metzke B, Neubauer WC, Hieke S, et al (2012). Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol Drug Saf. published online on 2012 May 28. doi: 10.1002/pds.3278, and accessed on Jun 2nd, 2012.
19 Misra R, Malik A, Singhal S (2011). Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species. Indian J Pathol Microbiol, 54, 112-6.   DOI
20 Miller MA, DiNunzio J, Matteucci ME, et al (2012). Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm, 38, 557-70.   DOI
21 Nicolle MC, Bénet T, Thiebaut A, et al (2011). Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 96, 1685-91.   DOI
22 Ohba H, Miwa S, Shirai M, et al (2012). Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med, 106, 724-9.   DOI
23 Reinwald M, Spiess B, Heinz WJ, et al (2012). Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012 Jun 1. doi: 10.1111/j.1600-0609.2012.01806.x.
24 Sambatakou H, Dupont B, Lode H, et al (2006). Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med, 119, 527.e17-24.   DOI
25 Schwartz S, Reisman A, Troke PF (2011). The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection, 39, 201-10.   DOI
26 Springer J, Schloßnagel H, Heinz W, et al (2012). A novel extraction method combining plasma with whole blood fraction shows excellent sensitivity and reproducibility in patients at high risk for invasive aspergillosis. J Clin Microbiol. 2012 May 16.
27 Wang ZY, Cai JP, Qiu LW, et al (2012). Development of monoclonal antibody-based galactomannoprotein antigencapture ELISAs to detect Aspergillus fumigatus infection in the invasive aspergillosis rabbit models. Eur J Clin Microbiol Infect Dis. 2012 Jun 5.
28 Stefan S, Markus R, Patricia R, et al (2005). Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood, 106, 2641-5.   DOI
29 Stopiglia CD, Arechavala A, Carissimi M, et al (2012). Standardization and characterization of antigens for the diagnosis of aspergillosis. Can J Microbiol, 58, 455-62.   DOI
30 Tabarsi P, Soraghi A, Marjani M, et al (2012). Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant, 10, 278-81.   DOI
31 White PL, Bretagne S, Klingspor L, et al (2010). Aspergillus PCR: one step closer to standardization. J Clin Microbiol, 48, 1231-40.   DOI
32 Wingard JR, Carter SL, Walsh TJ, et al (2010). Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 116, 5111-8.   DOI
33 Yan PW, Huang XE, Jiang Y, et al (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
34 Yuan X, Wang R, Bai CQ, et al(2012). Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials. Pharmazie, 67, 267-73.
35 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
36 Yu DS, Huang XE, Zhou JN (2012). A comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, in press.